近畿大学ライフサイエンス研究所Kindai University Life Science Research Institute

平成27年度

巻頭言

平成27年度
ライフサイエンス研究所紀要発刊によせて
前研究所長（平成28年10月1日の人事異動により）
工藤　正俊（内科学教室消化器内科部門教授）

　ライフサイエンス研究所は近畿大学本部直轄の組織で、医学部からは独立した研究施設ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、共同兼任の状態にあることから、医学部の研究に寄与するところが大きな施設といえるでしょう。
　私立大学医学部や私立医科大学で基礎的な研究に専念する医学部出身者は元来多くありませんでしたが、新臨床研修医制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけていると考えられます。
　しかし、時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことと考えます。基礎系および臨床系の多くの教室の多大な御尽力と、研究所の技術員の奮闘に敬意を表するとともに、引き続いての御協力をお願いする次第です。

平成27年度ライフサイエンス研究所紀要

内科学教室消化器内科部門（工藤　正俊　教授）

  1. 2015 Adachi T, Sakurai T, Kashida H, Mine H, Hagiwara S, Matsui S, Yoshida K, Nishida N, Watanabe T, Itoh K, Fujita J, Kudo M: Involvement of heat shock protein A4/Apg-2 in refractory inflammatory bowel disease. Inflamm Bowel Dis 21:31-39, 2015.
  2. 2015 Kudo M*: Malignant transformation of hepatocellular adenoma: How frequently does it happen? Liver Cancer 1:1-5, 2015.
  3. 2015 Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K: Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett 356:819-827, 2015.
  4. 2015 Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, Nowiem SE: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33:172-179, 2015.
  5. 2015 Okumura N, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Kawasaki M, Tomita T, Umehara Y, Taniike S, Kono M, Kudo M: Percutaneous endoscopic gastrostomy with Funada-style gastropexy greatly reduces the risk of peristomal infection. Gastroenterol Rep 3:69-74, 2015.
  6. 2015 Nishida N, Kudo M: A bridge between multi-omics data and the management of hepatocellular carcinoma. Ann Transl Med 3:1, 2015.
  7. 2015 Kudo M*: Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 4:39-50, 2015.
  8. 2015 Kudo M*: Clinical practice guidelines for hepatocellular carcinoma differ between Japan, United States, and Europe. Liver Cancer 4:85-95, 2015.
  9. 2015 Kitano M, Kamata K, Imai H, Miyata T, Yasukawa S, Yanagisawa A, Kudo M: Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliaty diseases. Digest Endosc 27:60-67, 2015.
  10. 2015 Shiina T, Nightingale K, Palmeri M, Hall T, Bamber J, Barr R, Castera L, Choi B, Chou Y, Cosgrove D, Dietrich C, Ding H, Amy D, Farrokh A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, Kudo M: WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1; basic principles and terminology. Ultrasound Med Biol 41:1126-1147, 2015.
  11. 2015 Kudo M*: Foreword to the WFUMB guideline and recommendations on the clinical use of ultrasound elastography. Ultrasound Med Biol 41:1125, 2015.
  12. 2015 Ferraioli G, Filice C, Castera L, Choi B, Sporea I, Wilson S, Cosgrove D, Dietrich C, Amy D, Bamber J, Barr R, Chou Y, Ding H, Farrokh A, Friedrich-Rust M, Hall T, Nakashima K, Nightingale K, Palmeri M, Schafer F, Shiina T, Suzuki S, Kudo M: WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part3; Liver. Ultrasound Med Biol 41:1161-1179, 2015.
  13. 2015 Barr R, Nakashima K, Amy D, Cosgrove D, Farrokh A, Schafer F, Bamber J, Castera L, Choi B, Chou Y, Dietrich C, Ding H, Ferraioli G, Filice C, Friedrich-Rust M, Hall T, Nightingale K, Palmeri M, Shiina T, Suzuki S, Sporea I, Wilson S, Kudo M: WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2; Breast. Ultrasound Med Biol 41:1148-1160, 2015.
  14. 2015 Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, Kudo M, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, Kumada H, and Peretinoin Study Group: Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized placebo-controlled trial.J Gastroenterol 50:667-674, 2015.
  15. 2015 Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H, Peretinoin Study Group: Peretinoin after curative therapy of hepatitits C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol 50:191-202, 2015.
  16. 2015 Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M, REACH Trail Investigators: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859-870, 2015.
  17. 2015 Sakurai T, Yada N, Watanabe T, Arizumi T, Hagiwara S, Ueshima K, Nishida N, Fujita J, Kudo M: Cold-inducible RNA-binding protein promotes the development of liver cancer. Cancer Sci 106:352-358, 2015.
  18. 2015 Arai Y, Yamashita K, Kuriyama K, Shiokawa M, Kodama Y, Sakurai T, Mizugishi K, Uchida K, Kadowaki N, Takaori-Kondo A, Kudo M, Okazaki K, Strober W, Chiba T, Watanabe T: Plasmacytoid dendritic cell activation and IFN-α production are prominent features of murine autoimmune pancreatitis and human lgG4-related autoimmune panreatitis. J Immunol 195:3033-3044, 2015.
  19. 2015 Kono M, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Okumura N, Kawasaki M, Tomita T, Umehara Y, Taniike S, Hatabe S, Funai S, Ono Y, Ochiai K, Maekura S, Kudo M*: Primary leiomyosarcoma of the colon. Clin J Gastroenterol 8:217-222, 2015.
  20. 2015 Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M and the investigators'study group: Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study. J Hepatol 63:896-904, 2015.
  21. 2015 Kudo M*: Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy. Hepatol Int 9:155-156, 2015.
  22. 2015 Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M: Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 35:2155-2166, 2015.
  23. 2015 Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Schwartz M, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts L, Sherman M: The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62:440-451, 2015.
  24. 2015 Sakurai T, Kashida H, Hagiwara S, Nishida N, Watanabe T, Fujita J, Kudo M: Heat shock protein A4 controls cell migration and gastric ulcer healing. Digest Dis Sci 60:850-857, 2015.
  25. 2015 Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 45:123-127, 2015.
  26. 2015 Pinato DJ, Arizumi T, Allara E, Jang JW, Smirne C, Kim YW, Kudo M, Pirisi M, Sharma R: Validation of the hepatoma arterial embolisation prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol H 13:1204-1208, 2015.
  27. 2015 Kudo M*: Chronic Liver Diseases and Liver Cancer: An Update in 2015. Digest Dis 33:705-707, 2015.
  28. 2015 Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, Kudo M*: Early viral response predicts the efficacy of antiviral triple therapy with simeprevir, peg-interferon, and ribavirin in patients infected with hepatitis C virus genotype 1. Digest Dis 33:708-714, 2015.
  29. 2015 Hasegawa Y, Kim SR, Hatae T, Ohta M, Fujinami A, Sugimoto K, Kim KI, Imoto S, Tohyama M, Kim SK, Ikura Y, Kudo M: Usefulness of cytokeratin-18M65 in diagnosing non-alcoholic steatohepatitis in Japanese population. Digest Dis 33:715-720, 2015.
  30. 2015 Sugimoto K, Kim SR, Imoto S, Tohyama M, Kim SK, Matsuoka T, Yano Y, Kudo M, Hayashi Y: Characteristics of hypovascular versus hypervascular well-differentiated hepatocellular carcinoma smaller than 2cm - focus on tumor size, markers and imaging detectability. Digest Dis 33:721-727, 2015.
  31. 2015 Arizumi T, Ueshima K, Iwanishi M, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M*: Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience second analysis. Digest Dis 33:728-734, 2015.
  32. 2015 Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, Kudo M*: Hepatic DNA methylation is affected by hepatocellular carcinoma risk in patients with and without hepatitis virus. Digest Dis 33:745-750, 2015.
  33. 2015 Kudo M*, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N: Subclassification of BCLC stage hepatocellular carcinoma and treatment strategies: Proposal of modified Bolondi subclassification (Kinki Criteria). Digest Dis 33:751-758, 2015.
  34. 2015 Minami Y, Murakami T, Kitano M, Sakurai T, Nishida N, Kudo M*: Cone-beam CT angiography for hepatocellular carcinoma: current status. Digest Dis 33:759-764, 2015.
  35. 2015 Kudo M*, Kitano M, Sakurai T, Nishida N: General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Digest Dis 33:765-770, 2015.
  36. 2015 Nishida N, Kitano M, Sakurai T, Kudo M*: Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma. Digest Dis 33:771-779, 2015.
  37. 2015 Kudo M*, Kitano M, Sakurai T, Nishida N: Challenges of clinical research on hepatocellular carcinoma. Digest Dis 33:780-790, 2015.
  38. 2015 Kudo M*: Evidence and consensus on management of hepatocellular carcinoma: update in 2015. Oncology 89:1-3, 2015.
  39. 2015 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M*: Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma. Oncology 89:4-10, 2015.
  40. 2015 Ogawa C, Minami Y, Noda T, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Kudo M*: Initial experience performing percutaneous ultrasound examination with real-time virtual sonography with color display. Oncology 89:11-18, 2015.
  41. 2015 Kariyama K, Wakuta A, Nishimura M, Kishida M, Oonishi A, Ohyama A, Nouso K, Kudo M: Percutaneous radiofrequency ablation for Intermediate-stage hepatocellular carcinoma. Oncology 89:19-26, 2015.
  42. 2015 Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Tsurusaki M, Yagyu Y, Ueshima K, Nishida N, Murakami T, Kudo M*: Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience. Oncology 89:27-32, 2015.
  43. 2015 Tochio H, Sugahara M, Imai Y, Tei H, Suginoshita Y, Iwasaki N, Sasaki I, Hamada M, Minowa K, Inokuma T, Kudo M*: Hyperenhanced rim surrounding liver metastatic tumors in the postvascular phase of sonazoid-enhanced ultrasonography: a histological indication of the presence of Kupffer cells. Oncology 89:33-41, 2015.
  44. 2015 Sugimoto K, Kim SR, Kim SK, Imoto S, Tohyama M, Kim KI, Ohtani A, Hatae T, Yano Y, Kudo M, Hayashi Y: Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma. Oncology 89:42-46, 2015.
  45. 2015 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Kitano M, Nishida N, Kudo M*: Validation of a modified substaging system (Kinki Criteria) for patients with intermediate-stage hepatocellular carcinoma. Oncology 89:47-52, 2015.
  46. 2015 Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ueshima K, Ida H, Nishida N, Kudo M*: A newly developed shear wave elastography modality: with a unique reliability index. Oncology 89:53-59, 2015.
  47. 2015 Kim SK, Kim SR, Imoto S, Tohyama M, Otono Y, Tamura T, Kim KI, Kobayashi M, Ohtani A, Sugimoto K, Mizuguchi A, Hiramatsu Y, Kudo M: Recent advances in the management of chronic hepatitis B including suppression of hepatocellular carcinoma by entecavir and interferon. Oncology 89:60-69, 2015.
  48. 2015 Hagiwara S, Nishida N, Kudo M: Antiviral therapy for chronic hepatitis B: combination of nucleoside analogs and interferon. World J Hepatol 7:2427-2431, 2015.
  49. 2015 Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre MA, Meinhardt G, Llovet JM: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16:1344-1354, 2015.
  50. 2015 Ueshima K, Kudo M*, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S: Phase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil. Liver Cancer 4:263-273, 2015.
  51. 2015 Kudo M*: Molecular targeted therapy for hepatocellular carcinoma: where are we now? Liver Cancer 4:1-7, 2015.
  52. 2015 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M*: Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer 4:253-262, 2015.
  53. 2015 Kudo M*: Immune checkpoint blockade in hepatocellular carcinoma. Liver Cancer 4:201-207, 2015.
  54. 2015 Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin SK, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M: Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 26:2457-2463, 2015.
  55. 2015 Yamao K, Kitano M, Kudo M, Maenishi O: Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration. Endoscopy 47:E596-597, 2015.
  56. 2015 Hagiwara S, Nishida N, Park AM, Sakurai T, Kawada A, Kudo M: Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria. Hepatology 62:1638-1689, 2015.
  57. 2015 Okada M, Murakami T, Yada N, Numata K, Onoda M, Hyodo T, Inoue T, Ishii K, Kudo M: Comparison between T1 relaxation time of Gd-EOB-DTPA enhanced MRI and li ver stiffness measurement of Ultrasound elastography in the evaluation of cirrhotic liver. J Magn Reson Imaging 41:329-338, 2015.
  58. 2015 Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T, Kokudo N, for the Liver Cancer Study Group of Japan: A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: A nationwide study of 11, 950 patients. Ann Surg 261:513-520, 2015.
  59. 2015 Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, Liver Cancer Study Group of Japan: Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 122:61-70, 2015.
  60. 2015 Minami Y, Kudo M*: Imaging modalities for assessment of treatment response to nonsurgical hepatocellular carcinoma therapy: Contrast-enhanced US, CT and MRI. Liver Cancer 4:106-114, 2015.
  61. 2015 Minaga K, Kitano M, Imai H, Miyata T, Kudo M: Acute spinal cord infarction after EUS-guided celiac plexus neurolysis. Gastrointest Endosc, 2015.
  62. 2015 Matsui S, Kudo M*, Kitano M, Asakuma Y: Evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS. Hepato-Gastroenterol 62:595-598, 2015.
  63. 2015 Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, Kudo M, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M: Multicenter cooperative case survey of hepatitis B Virus reactivation by chemotherapeutic agents. Hepatol Res 45:1220-1227, 2015.
  64. 2015 Kudo M*: Locoregional therapy for hepatocellular carcinoma. Liver Cancer 4:163-164, 2015.
  65. 2015 Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kudo M, Noguchi M: Phase II study of personalized peptide vaccination with both a hepatitis C virus-derived peptide and peptides from tumor-associated antigens for the treatment of HCV-positive advanced hepatocellular carcinoma patients. J Immunol Res 2015; 2015: 473909. doi: 10.1155/2015/473909. Epub 2015 Oct 11.
  66. 2016 Kudo M*: Defect reperfusion imaging with sonazoid®: a breakthrough in hepatocellular carcinoma. Liver Cancer 5:1-7, 2016.
  67. 2016 Kudo M*: Breakthrough imaging in hepatocellular carcinoma. Liver Cancer 5:47-54, 2016.
  68. 2016 Kamata K, Kitano M, Omoto S, Kadosaka K, Miyata T, Yamao K, Imai H, Sakamoto H, Harwani Y, Chikugo T, Chiba Y, Matsumoto I, Takeyama Y, Kudo M: Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cysts. Endoscopy 48:35-41, 2016.
  69. 2016 Kudo M*, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, Furuse J, Murakami T, Kadoya M, Kokudo N, Liver Cancer Study Group of Japan: Response evaluation criteria in cancer of the liver (RECICL)(2015 revised version). Hepatol Res 46:3-9, 2016.
  70. 2016 Inoue T, Hyodo T, Korenaga K, Murakami T, Imai Y, Higaki A, Suda T, Takano T, Miyoshi K, Koda M, Tanaka H, Iijima H, Ochi H, Hirooka M, Numata K,Kudo M: Kupffer phase image of Sonazoiod-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: A multicenter retrospective study. J Gastroenterol 51:144-152, 2016.
  71. 2016 Kudo M*: Heterogeneity and subclassification of Barcelona Clinic Liver Cancer Stage B. Liver Cancer 5:91-96, 2016.
  72. 2016 Miyata T, Kitano M, Omoto S, Kadosaka K, Kamata K, Imai H, Sakamoto H, Nishida N, Harwani Y, Murakami T, Takeyamas Y, Chiba Y, Kudo M: Contrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreatobiliary carcinoma. World J Gastroenterol 22:3381-3391, 2016.
  73. 2016 Kudo M, Kanai H: Inclusion of Journal of Medical Ultrasonics in MEDLINE. J Med Ultrason 43:163, 2016.
  74. 2016 Kamata K, Kitano M, Yasukawa S, Kudo M, Chiba Y, Ogura T, Higuchi K, Fukutake N, Ashida R, Yamasaki T, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Yanagisawa A: Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trial. Endoscopy 48:1-7, 2016.
  75. 2016 Hagiwara S, Nishida N, Kudo M: Reply. Hepatology 63:1744-1745, 2016.
  76. 2016 Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R: TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib). Radiology 279:630-640, 2016.
  77. 2016 Watanabe T, Sadakane Y, Yagama N, Sakurai T, Ezoe H, Kudo M, Chiba T, Strober W: Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis. Mucosal Immunol, 2016 (epub ahead of print).
  78. 2016 Imai H, Kitano M, Omoto S, Kadosaka K, Kamata K, Miyata T, Yamao K, Sakamoto H, Harwani Y, Kudo M: EUS-guided gallbladder drainage for rescue treatment of malignant distal biliary obstruction after unsuccessful ERCP. Gastrointest Endosc, 84:147-151, 2016.
  79. 2016 Hagiwara S, Nishida N, Kudo M: Hepatocyte damage due to protoporphyrin deposition. Hepatology, 2016 (epub ahead of print).
  80. 2016 Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyi S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ: Randomized Phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol, 2016 (epub ahead of print).
  81. 2016 Nishikawa H, Enomoto H, Saito M, Aizawa N, Tsuda Y, Higuchi K, Okazaki K, Seki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M, Osaki Y, Nishiguchi S: Treatment response and tolerability in elderly patients with chronic hepatitis C: subgroup analysis in ReGIT-J study. Acta Gastro-Ent Belg, 2016 (in press).
  82. 2016 Ye SL, Lencioni R, Marrero JA, Venook AP, Nakajima K, Kudo M: Treatment patterns in >3000 sorafenib-treated patients: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib). Chinese Society of Clinical Oncology (CSCO), 2016 (in press).
  83. 2016 Kitai S, Kudo M*, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver Cancer Study Group of Japan: Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Liver Cancer, 2016 (in press).
  84. 2016 Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JFH, Ladron de Guevara L, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R: Observational registry study of sorafenib use in clinical practice across Child-Pugh subgroups: final analysis of GIDEON. J Hepatol, 2016 (in press).
  85. 2016 Kudo M*, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y: A randomized, double-blind, placebo-controlled phase III trial of orantinib combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma (ORIENTAL). J Clin Oncol, 2016 (in press).
  86. 2016 Matsui S, Kudo M, Kashida H: Gastric perineurioma. Am J Gastroenterol 111:453, 2016.
  87. 2016 Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon R: Randomized, open-label phase 2 study comparing frontline dovitinib vs sorafenib in patients with advanced hepatocellular carcinoma. Hepatology, 2016 (in press).
  88. 2016 Minaga K, Kitano M, Yamashita Y, Nakatani Y, Kudo M: Stent migration into the abdominal cavity after endoscopic ultrasound-guided hepaticogastrostomy. Gastrointest Endosc, 2016 (in press).
  89. 2016 Nishida N, Yada N, Hagiwara S, Sakurai T, Kitano M, Kudo M: Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. J Gastroen Hepatol, 2016 (in press).
  90. 2016 Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JFH, Ladron de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL: Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int, 2016 (in press).
  91. 2016 Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y, and the Liver Cancer Study Group of Japan: Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res, 2016 (in press).
  92. 2016 Hagiwara S, Nishida N, Sakurai T, Park AM, Komeda Y, Kitano M, Kudo M: Identification of a HBx mutation that enhances human hepatocarcinogenesis through the activation of the JNK and Wnt pathways. BMC Cancer, 2016 (in press).
  93. 2016 Kudo M, Ikeda M, Takayama T, Numata K, Izumi N, Furuse J, Okusaka T, Kadoya M, Yamashita S, Ito Y, Kokudo N: Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. J Gastroenterol, 2016 (in press).
  94. 2016 Pinato D, Arizumi T, Jang JW, Allara E, Suppiah P, Smirne C, Kim Y, Pirisi M, Kudo M, Sharma R: Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. Oncotarget, 2016 (in press).
  95. 2016 Minami Y, Takita M, Tsurusaki M, Yagyu Y, Ueshima K, Murakami T, Kudo M: Semi-quantitative Prediction of Early Response of Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma using Postprocedural Plain Cone-beam CT. Hepatol Res, 2016 (in press).
  96. 2016 Yamao K, Kitano M, Kayahara T, Ishida E, Yamamoto H, Minaga K, Yamashita Y, Nakajima J, Asada M, Okabe Y, Osaki Y, Chiba Y, Imai H, Kudo M: Factors predicting through-the-scope gastroduodenal stenting outcomes in patients with gastric outlet obstruction: a large multicenter retrospective study in West Japan. Gastrointest Endosc, 2016 (in press).
  97. 2016 Kudo M*: Risk of Hepatocellular carcinoma in patients with hepatitis C virus who achieved sustained virological response. Liver Cancer, 2016 (in press).
  98. 2016 Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver Cancer Study Group of Japan: Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer, 2016 (in press).
  99. 2016 Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L: Hepatocellular carcinoma: therapeutic guidelines and medical treatment. Liver Cancer, 2016 (in press).
  100. 2016 Nishida N, Kudo M, et al: Serum microRNA profile that predict initial effect of sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer, 2016 (in press).
  101. 2016 Kudo M: Preface. Digest Dis, 2016 (in press).
  102. 2016 Hagiwara S, Kudo M, et al: Daclatasvir plus asunaprevir combination therapy for the hepatitis C. Digest Dis, 2016 (in press).
  103. 2016 Nishida N, Kudo M, et al: Safety and tolerability of sofosbuvir and rivavirin combination therapy for elderly patients infected with hepatitis C genotype 2. Digest Dis, 2016 (in press).
  104. 2016 Hagiwara S, Kudo M, et al: Sofosbuvir plus redipasvir combination therapy for the hepatitis C. Digest Dis, 2016 (in press).
  105. 2016 Nishida N, Kudo M, et al: Effect and safety of sofosbuvir/ledipasvir therapy in patients with chronic hepatitis C genotype 1 with moderate chronic kidney disease. Digest Dis, 2016 (in press).
  106. 2016 Yada N, Kudo M, et al: Diagnostic performance of liver fibrosis by ultrasound shear wave imaging with a unique reliability index. Digest Dis, 2016 (in press).
  107. 2016 Takita M, Kudo M, et al: Percutaneous Aspiration and Ethanolamine Oleate Sclerotherapy for hepatic cyst. Digest Dis, 2016 (in press).
  108. 2016 Kono M, Kudo M, et al: Low mechanical index tissue harmonic imaging with ultrasound contrast in focal hepatic lesions. Digest Dis, 2016 (in press).
  109. 2016 Chishina H, Kudo M, et al: Effect on refractory ascites prediction factor of TLV. Digest Dis, 2016 (in press).
  110. 2016 Yada N, Kudo M, et al: Evaluation of liver condition by combinational use of ultrasound shear wave imaging and ultrasound strain imaging. Digest Dis, 2016 (in press).
  111. 2016 Nishida N, Kudo M, et al: Effect of intensive-combination therapy with branched-chain amino acids and levocarnitine chloride for patients with decompensated liver cirrhosis with malnutrition. Digest Dis, 2016 (in press).
  112. 2016 Takita M, Kudo M, et al: Staging of hepatocellular carcinoma assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 39,171 patients in Japan. Digest Dis, 2016 (in press).
  113. 2016 Minami Y, Kudo M, et al: Can the ablative hyperechoic area be regarded as a necrotic lesion after radio frequency ablation of the liver? Digest Dis, 2016 (in press).
  114. 2016 Ogawa C, Kudo M, et al: Prediction of embolization area after conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using SYNAPSE VINCENT. Digest Dis, 2016 (in press).
  115. 2016 Kudo M: Immune check point blockade in hepatocellular carcinoma: An update in 2016. Digest Dis, 2016 (in press).
  116. 2016 Kim SK, Kudo M, et al: Efficacy and safety of sofosbuvir plus ribavirin therapy for patients with chronic hepatitis C genotype 2. Digest Dis, 2016 (in press).
  117. 2016 Nagai T, Kudo M, et al: Impact of TJP-1 and TWIST expression on post-operative prognosis in hepatocellular carcinoma. Digest Dis, 2016 (in press).
  118. 2016 Imoto S, Kudo M, et al: Serum IFNL3 levels in patients with acute hepatitis C virus infection. Digest Dis, 2016 (in press).
  119. 2016 Seo K, Kudo M, et al: Association between coffee intake and liver enzymes in indigenous Japanese and Korean immigrants. Digest Dis, 2016 (in press).
  120. 2016 Kawasaki T, Hata KY, Kinoshita D, Takayama M, Okuda H, Mizuno S, Kudo M: Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. Digest Dis, 2016 (in press).
  121. 2015 Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H: Phase 2 Study of Lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol, 2016 (in press).

病理学教室（伊藤　彰彦　教授）

  1. Yoneshige A, Hagiyama M, Fujita M, Ito A.
    Pathogenic Actions of Cell Adhesion Molecule 1 in Pulmonary Emphysema and Atopic Dermatitis.
    Front Cell Dev Biol. 2015 Nov 20;3:75.
  2. Fujita M, Matsui T, Ito A.
    Biomedical insights into cell adhesion and migration-from a viewpoint of central nervous system tumor immunology.
    Front Cell Dev Biol. 2015 Oct 14;3:55.
  3. Hagiyama M, Yoneshige A, Inoue T, Sato Y, Mimae T, Okada M, Ito A.
    The intracellular domain of cell adhesion molecule 1 is present in emphysematous lungs and induces lung epithelial cell apoptosis.
    J Biomed Sci. 2015 Aug 11;22:67.
  4. Yoneshige A, Hagiyama M, Inoue T, Mimae T, Kato T, Okada M, Enoki E, Ito A.
    Increased ectodomain shedding of cell adhesion molecule 1 as a cause of type II alveolar epithelial cell apoptosis in patients with idiopathic interstitial pneumonia.
    Respir Res. 2015 Aug 1;16:90.
  5. Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K.
    Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    PLoS One. 2015 May 8;10(5):e0121891.
  6. Sakai K, Yoneshige A, Ito A, Ueda Y, Kondo S, Nobumasa H, Fujita Y, Togashi Y, Terashima M, De Velasco MA, Tomida S, Nishio K.
    Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.
    Springerplus. 2015 Jan 5;4:7.
  7. 村上哲平,井上敬夫,西村俊司,伊藤彰彦,赤木將男
    上皮悪性腫瘍の肉腫様変化は骨芽細胞文化の側面を有する：骨分化マーカーを用いた検討と解析
    近畿大医誌（Med J Kinki Univ） 第40巻１, ２号　39～46 2015

細菌学教室（義江　修　教授）

  1. Yasuda Y, Fujita M, Koike E, Obata K, Shiota M, Kotani Y, Musha T, Tsuji-Kawahara S, Sato T, Masuda S, Okano J, Yamasaki H, Okumoto K, Uesugi T, Nakao S, Hoshiai H, Mandai M. Erythropoietin receptor antagonist suppressed ectopic hemoglobin synthesis in xenografts of HeLa cells to promote their destruction. PLoS One. 10:e0122458 (2015)
  2. Otsubo D, Yamashita K, Fujita M, Nishi M, Kimura Y, Hasegawa H, Suzuki S, Kakeji Y. Early-phase administration of low-dose 5-fluorouracil and early-phase resection of the established melanoma prevents the formation of lung metastases by inhibiting MDSC generation and accumulation. Anticancer Res. 35:4425 (2015)
  3. Fujita M, Shintai K, Nakata S, Maeda N, Hatano N, Seki Y. Intimo-intimal intussusception: a rare form of common carotid artery dissection. J Vasc Interv Radiol. 26:1414 (2015)
  4. Fujita M, Matsui T, Ito A. Biomedical insights into cell adhesion and migration -- from a viewpoint of central nervous system tumor immunology. Front Cell Dev Biol. 3:55 (2015)
  5. Yoneshige A, Hagiyama M, Fujita M, Ito A. Pathogenic Actions of Cell Adhesion Molecule 1 in Pulmonary Emphysema and Atopic Dermatitis. Front Cell Dev Biol. 3:75 (2015)
  6. Motoshima T, Komohara Y, Hasita Horlad, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M. CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower faction of monocytes. Oncol Lett. doi: 10.3892/or.2015.3893 (2015)
  7. Moriguchi K, Miyamoto K, Tanaka N, Ueno R, Nakayama T, Yoshie O, Kusunoki S.C-C chemokine receptor type 4 antagonist Compound 22 ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2016 Feb 15;291:54-8.
  8. Matsuo K, Koizumi K, Fujita M, Morikawa T, Jo M, Shibahara N, Saiki I, Yoshie O, Nakayama T.Efficient Use of a Crude Drug/Herb Library Reveals Ephedra Herb As a Specific Antagonist for TH2-Specific Chemokine Receptors CCR3, CCR4, and CCR8. Front Cell Dev Biol. 2016 Jun 7;4:54.
  9. Park AM, Kanai K, Itoh T, Sato T, Tsukui T, Inagaki Y, Selman M, Matsushima K, and Yoshie O. Heat Shock Protein 27 Plays a Pivotal Role in Myofibroblast Differentiation and in the Development of Bleomycin-Induced Pulmonary Fibrosis. PLoS One. 2016 Feb 9;11(2):e0148998.
  10. Nagakubo D, Yoshie O, Hirata T.Upregulated CCL28 expression in the nasal mucosa in experimental allergic rhinitis: Implication for CD4(+) memory T cell recruitment. Cell Immunol. 2016 Apr;302:58-62.
  11. Park AM, Hagiwara S, Hsu DK, Liu FT, Yoshie O.Galectin-3 Plays an Important Role in Innate Immunity to Gastric Infection by Helicobacter pylori. Infect Immun. 2016 Mar 24;84(4):1184-93.
  12. Matsuo K, Itoh T, Koyama A, Imamura R, Kawai S, Nishiwaki K, Oiso N, Kawada A, Yoshie O, Nakayama T.CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma. Cancer Lett. 2016 Aug 1;378(1):16-22.
  13. Tasaki T, Fujita M, Okuda T, Yoneshige A, Nakata S, Yamashita K, Yoshioka H, Kato A. Overexpression of MET in glioblastoma enhances tumorigenicity of glioma stem cells. Anticancer Res. 36:xxxx (2016 in press)
  14. Yamashita K, Hasegawa H, Fujita M, Nishi M, Tanaka T, Arimoto A, Suzuki S, Kamigaki T, Kakeji Y.Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer. Anticancer Res. 2016 Jul;36(7):3659-65.

ゲノム生物学教室（西尾　和人　教授）

  1. Fujita Y, Kimura M, Sato H, Takata T, Ono N, Nishio K.
    Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells.
    Arch Pharm Res. 2016 Jun;39(6):825-32.
  2. Mizuuchi H, Suda K, Murakami I, Sakai K, Sato K, Kobayashi Y, Shimoji M, Chiba M, Sesumi Y, Tomizawa K, Takemoto T, Sekido Y, Nishio K, Mitsudomi T.
    Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
    Cancer Sci. 2016 Apr;107(4):461-8.
  3. Watanabe S, Takeda M2, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K.
    Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
    Invest New Drugs. 2016 Jun;34(3):394-6.
  4. Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.
    Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
    Clin Cancer Res. 2016 Jan 29. [Epub ahead of print]
  5. Takeda M, Sakai K, Okamoto K, Hayashi H, Tanaka K, Shimizu T, Nishio K, Nakagawa K.
    Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.
    Ann Oncol. 2016 Apr;27(4):748-50.
  6. Suda K, Murakami I, Sakai K, Tomizawa K, Mizuuchi H, Sato K, Nishio K, Mitsudomi T.
    Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Lung Cancer. 2016 Jan;91:36-40.
  7. Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.
    HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
    Oncotarget. 2016 Jan 19;7(3):3453-60.
  8. De Velasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H.
    Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    Oncotarget. 2016 Mar 29;7(13):15959-76.
  9. Tanaka Y, Aoyagi K, Minashi K, Komatsuzaki R, Komatsu M, Chiwaki F, Tamaoki M, Nishimura T, Takahashi N, Oda I, Tachimori Y, Arao T, Nishio K, Kitano S, Narumi K, Aoki K, Fujii S, Ochiai A, Yoshida T, Muto M, Yamada Y, Sasaki H.
    Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy.
    PLoS One. 2015 Dec 1;10(12):e0143804.
  10. Togashi Y, Mizuuchi H, Tomida S, Terashima M, Hayashi H, Nishio K, Mitsudomi T.
    MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.
    Lung Cancer. 2015 Dec;90(3):590-7.
  11. Yonesaka K, Takegawa N, Satoh T, Ueda H, Yoshida T, Takeda M, Shimizu T, Chiba Y, Okamoto I, Nishio K, Tamura T, Nakagawa K.
    Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.
    PLoS One. 2015 Nov 16;10(11):e0143132.
  12. Takeda M, Sakai K, Terashima M, Kaneda H, Hayashi H, Tanaka K, Okamoto K, Takahama T, Yoshida T, Iwasa T, Shimizu T, Nonagase Y, Kudo K, Tomida S, Mitsudomi T, Saigo K, Ito A, Nakagawa K, Nishio K.
    Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.
    Ann Oncol. 2015 Dec;26(12):2477-82.
  13. Suda K, Murakami I, Sakai K, Mizuuchi H, Shimizu S, Sato K, Tomizawa K, Tomida S, Yatabe Y, Nishio K, Mitsudomi T.
    Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Sci Rep. 2015 Sep 24;5:14447.
  14. Nagai H, Oiso N, Tomida S, Sakai K, Fujiwara S, Nakamachi Y, Kawano S, Kawada A, Nishio K, Nishigori C.
    Epidermolysis bullosa simplex with mottled pigmentation with noncicatricial alopecia: identification of a recurrent p.P25L mutation in KRT5 in four affected family members.
    Br J Dermatol. 2016 Mar;174(3):633-5.
  15. Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Okamoto I, Nishio K, Nakagawa K.
    The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Oncotarget. 2015 Oct 20;6(32):33602-11.
  16. Yoshioka Y, Togashi Y, Chikugo T, Kogita A, Taguri M, Terashima M, Mizukami T, Hayashi H, Sakai K, de Velasco MA, Tomida S, Fujita Y, Tokoro T, Ito A, Okuno K, Nishio K.
    Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.
    Cancer. 2015 Dec 15;121(24):4359-68.
  17. Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, Okamoto I, Nishio K, Hoshino T.
    Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Oncotarget. 2015 Oct 13;6(31):30850-8.
  18. Murao T, Shiotani A, Fujita Y, Yamanaka Y, Kamada T, Manabe N, Hata J, Nishio K, Haruma K.
    Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk.
    J Gastroenterol Hepatol. 2016 Jan;31(1):99-106.
  19. Iwamoto Y, Mitsudomi T, Sakai K, Yamanaka T, Yoshioka H, Takahama M, Yoshimura M, Yoshino I, Takeda M, Sugawara S, Kawaguchi T, Takahashi T, Ohta M, Ichinose Y, Atagi S, Okada M, Saka H, Nakagawa K, Nakanishi Y, Nishio K.
    Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2015 Dec 1;21(23):5245-52.
  20. Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T.
    EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
    Clin Cancer Res. 2015 Dec 1;21(23):5305-13.
  21. Suzuki T, Ishibashi K, Yumoto A, Nishio K, Ogasawara Y.
    Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells.
    Oncol Lett. 2015 Aug;10(2):805-809.
  22. Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne PA, Nakagawa K.
    Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
    Oncogene. 2016 Feb 18;35(7):878-86.
  23. Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakajima TE, Boku N, Nishio K.
    EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
    Int J Oncol. 2015 Aug;47(2):499-505.
  24. Sakai K, Takeda H, Nishijima N, Orito E, Joko K, Uchida Y, Izumi N, Nishio K, Osaki Y.
    Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
    Oncotarget. 2015 Aug 28;6(25):21636-44.
  25. Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Banno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.
    An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.
    Ann Oncol. 2015 Aug;26(8):1800-1.
  26. Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K.
    A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
    Br J Cancer. 2015 Mar 3;112(5):819-24.
  27. Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y.
    Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
    Cancer Sci. 2015 Jul;106(7):883-90.
  28. Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K.
    Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    PLoS One. 2015 May 8;10(5):e0121891.
  29. Yamamoto Y, De Velasco MA, Kura Y, Nozawa M, Hatanaka Y, Oki T, Ozeki T, Shimizu N, Minami T, Yoshimura K, Yoshikawa K, Nishio K, Uemura H.
    Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
    J Transl Med. 2015 May 8;13:150.
  30. Mizuuchi H, Suda K, Sato K, Tomida S, Fujita Y, Kobayashi Y, Maehara Y, Sekido Y, Nishio K, Mitsudomi T.
    Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.
    PLoS One. 2015 Apr 14;10(4):e0123901.
  31. Koike H, Nozawa M, De Velasco MA, Kura Y, Ando N, Fukushima E, Yamamoto Y, Hatanaka Y, Yoshikawa K, Nishio K, Uemura H.
    Conditional PTEN-deficient mice as a prostate cancer chemoprevention model.
    Asian Pac J Cancer Prev. 2015;16(5):1827-31.
  32. Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K.
    Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer.
    Anticancer Res. 2015 Mar;35(3):1683-9.
  33. Togashi Y, Hayashi H, Okamoto K, Fumita S, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.
    Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.
    Lung Cancer. 2015 Apr;88(1):16-23.
  34. Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K.
    Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.
    Cancer Lett. 2015 Jan 28;356(2 Pt B):819-27.
  35. Kogita A, Yoshioka Y, Sakai K, Togashi Y, Sogabe S, Nakai T, Okuno K, Nishio K.
    Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Biochem Biophys Res Commun. 2015 Feb 27;458(1):52-6.
  36. Sakai K, Yoneshige A, Ito A, Ueda Y, Kondo S, Nobumasa H, Fujita Y, Togashi Y, Terashima M, De Velasco MA, Tomida S, Nishio K.
    Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.
    Springerplus. 2015 Jan 5;4:7.
  37. Banno E, Togashi Y, Kobayashi Y, Hayashi H, Mitsudomi T, Nishio K.
    Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
    Anticancer Res. 2015 Apr;35(4):2005-8.
  38. Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.
    Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Int J Oncol. 2015 Mar;46(3):1025-30.

archive

近畿大学
近畿大学医学部

Copyright (C) Kindai University Life Science Research Institute All rights reserved.